Skip to main content
Medical information Clinical review pending

Cytogenetics

Fishmonosomy 7 Del7q31 for AML MDS Test

The Fishmonosomy 7 Del7q31 for AML MDS Test uses FISH technology to detect specific chromosomal abnormalities (Monosomy 7, del7q31) associated with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), aiding in diagnosis and treatment planning.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
5 mL (3 mL minimum) whole blood OR 4 mL (2 mL minimum) bone marrow collected in 2 Green Top (Sodium Heparin) tubes.
Results
Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required. Ensure the sample is collected correctly and transported promptly.
Test priceKSh 12,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Fishmonosomy 7 Del7q31 for AML MDS Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Diagnosis of suspected Acute Myeloid Leukemia (AML)
  • ✓Diagnosis of suspected Myelodysplastic Syndromes (MDS)
  • ✓Risk stratification in AML/MDS
  • ✓Monitoring disease progression
  • ✓Evaluating response to therapy
  • ✓Patients with unexplained cytopenias
  • ✓Patients with symptoms suggestive of blood cancer
02

In plain language

What this test helps you understand

This test helps diagnose and classify AML and MDS by identifying specific chromosomal abnormalities (Monosomy 7, del7q31). The results can inform prognosis and guide treatment decisions.
The Fishmonosomy 7 Del7q31 for AML MDS Test is an advanced diagnostic procedure used to evaluate patients suspected of having acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). This test identifies specific chromosomal abnormalities, namely Monosomy 7 (loss of one copy of chromosome 7) and deletion at 7q31 (loss of a part of the long arm of chromosome 7). These genetic changes are important markers for understanding the disease and guiding treatment decisions.

This test utilizes Fluorescence In Situ Hybridization (FISH) methodology, which involves using fluorescent probes that bind to specific parts of chromosomes. By analyzing the pattern of fluorescence under a microscope, laboratory professionals can detect the presence or absence of the targeted chromosomal abnormalities in a sample of blood or bone marrow.

Understanding the results of this test is crucial for healthcare providers to determine the prognosis and select the most appropriate treatment strategy for patients with AML or MDS. It can also help in monitoring the effectiveness of treatment and detecting potential disease progression.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required. Ensure the sample is collected correctly and transported promptly.
Sample5 mL (3 mL minimum) whole blood OR 4 mL (2 mL minimum) bone marrow collected in 2 Green Top (Sodium Heparin) tubes.
MethodologyFluorescence In Situ Hybridization (FISH) on blood or bone marrow cells.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects only the specific chromosomal abnormalities targeted by the probes (Monosomy 7, del7q31). It does not detect other chromosomal abnormalities or gene mutations. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

FISH stands for Fluorescence In Situ Hybridization. It is a laboratory technique that uses fluorescent probes to detect specific DNA sequences or chromosomal abnormalities.
Detecting Monosomy 7 or del7q31 can provide important information about the type of AML or MDS, its potential behavior, and help guide treatment choices.
A sample of either whole blood or bone marrow is required for this test.
Samples should be shipped at 18-22°C and must not be frozen. Please refer to the laboratory's specific transport guidelines.
Turnaround time varies. Please contact the laboratory for specific details.
Results indicate the presence or absence of Monosomy 7 and del7q31. Your doctor will interpret these results in the context of your overall health condition.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp